Fig. 3.

Incidence of adverse clinical outcomes in patients with UC. For hospitalization and surgery, patients with events occurring during both first and second lines of biologic treatment were counted individually for each line of treatment. Overall totals count only the first event and therefore do not equal the sum of patients with events during first and second lines of biologic treatment. Dysplasia, CRC, and infection were counted for the line of treatment incident with the event onset; therefore, overall totals equal the sum of patients with events during first and second lines of biologic treatment. ADA, adalimumab; CRC, colorectal cancer; IFX, infliximab; UC, ulcerative colitis; VDZ, vedolizumab